Abstract
The renin-angiotensin-aldosterone system blockade is a key component in the modern management of cardiovascular diseases. Agents that interfere with the different components of this system such as angiotensin converting enzyme inhibitors, sartans and mineralocorticoid receptor antagonists represent valuable therapeutic tools to reduce cardiovascular risk in brachial blood pressure independent mechanisms. Indeed, antagonists of the renin-angiotensin-aldosterone system reduce inflammation, oxidative stress and vascular remodeling in hypertension beyond blood pressure reduction and have demonstrated better cardiovascular protection compared with some of the other antihypertensive agents, especially in selected populations such as patients with diabetes and renal failure. These advantages were confirmed recently in several large-scale randomized trials. Latest evidence suggests that the effect of some antihypertensive drugs on central blood pressure is greater when compared with the effect on peripheral pressure. Nowadays, there is growing agreement that relatively greater influence of agents blocking renin-angiotensin system on central blood pressure may at least partly explain their advantages over other antihypertensives in many clinical situations. Clinical consequences of overestimation of the antihypertensive effect of some drug classes and underestimation blood pressure changes in patients treated with angiotensin converting enzyme inhibitors when analyzing brachial instead of central blood pressure is being increasingly recognized recently.
Keywords: Renin-angiotensin-aldosterone system, angiotensin converting enzyme inhibitors, sartans, mineralocorticoid receptor antagonists, hypertension, central blood pressure, cardiovascular risk, pleiotropic effects
Current Pharmaceutical Design
Title: Pleiotropic Effects of Drugs Inhibiting the Renin-Angiotensin-Aldosterone System
Volume: 15 Issue: 5
Author(s): P. Jankowski, M. E. Safar and A. Benetos
Affiliation:
Keywords: Renin-angiotensin-aldosterone system, angiotensin converting enzyme inhibitors, sartans, mineralocorticoid receptor antagonists, hypertension, central blood pressure, cardiovascular risk, pleiotropic effects
Abstract: The renin-angiotensin-aldosterone system blockade is a key component in the modern management of cardiovascular diseases. Agents that interfere with the different components of this system such as angiotensin converting enzyme inhibitors, sartans and mineralocorticoid receptor antagonists represent valuable therapeutic tools to reduce cardiovascular risk in brachial blood pressure independent mechanisms. Indeed, antagonists of the renin-angiotensin-aldosterone system reduce inflammation, oxidative stress and vascular remodeling in hypertension beyond blood pressure reduction and have demonstrated better cardiovascular protection compared with some of the other antihypertensive agents, especially in selected populations such as patients with diabetes and renal failure. These advantages were confirmed recently in several large-scale randomized trials. Latest evidence suggests that the effect of some antihypertensive drugs on central blood pressure is greater when compared with the effect on peripheral pressure. Nowadays, there is growing agreement that relatively greater influence of agents blocking renin-angiotensin system on central blood pressure may at least partly explain their advantages over other antihypertensives in many clinical situations. Clinical consequences of overestimation of the antihypertensive effect of some drug classes and underestimation blood pressure changes in patients treated with angiotensin converting enzyme inhibitors when analyzing brachial instead of central blood pressure is being increasingly recognized recently.
Export Options
About this article
Cite this article as:
Jankowski P., Safar E. M. and Benetos A., Pleiotropic Effects of Drugs Inhibiting the Renin-Angiotensin-Aldosterone System, Current Pharmaceutical Design 2009; 15 (5) . https://dx.doi.org/10.2174/138161209787315747
DOI https://dx.doi.org/10.2174/138161209787315747 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic:Translating Clinical Evidence into the Practice of Diabetes Care (Guest Editor: Richard W. Grant Contents)]
Current Diabetes Reviews Nutrition Transition and Obesity Among Teenagers and Young Adults in South Asia
Current Diabetes Reviews Effects of Endothelins on Cardiac and Vascular Cells: New Therapeutic Target for the Future?
Current Vascular Pharmacology Current Approaches to the Diagnosis of Classical form of Congenital Adrenal Hyperplasia
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Medicinal Chemistry of Antimigraine Drugs
Current Medicinal Chemistry Angiotensin II Type 1 and Type 2 Receptor-induced Cell Signaling
Current Pharmaceutical Design Insulin Therapy for Improving Cardiac Surgical Outcomes
Current Drug Targets Alzheimer’s Disease and the Early Signs of Age-Related Macular Degeneration
Current Alzheimer Research Hypertension to Heart Failure: New Developmental Strategies do not Cross a Clinical and Therapeutic Divide
Current Pharmaceutical Design The Role of PPARs in Obesity and other Insulin Resistance Associated Disorders
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Atherosclerosis - New Targets and Therapeutics
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Angiogenesis and Microvasculature in the Female Reproductive Organs: Physiological and Pathological Implications
Current Pharmaceutical Design Metabolic Syndrome as a Modifier of Atherosclerosis in Murine Models
Current Drug Targets Regulation of Angiotensin II Receptor Expression
Current Pharmaceutical Design Calcium Intake Requirements Along the Life Cycle and Associated Factors
Current Nutrition & Food Science Vitamin D/VDR in Acute Kidney Injury: A Potential Therapeutic Target
Current Medicinal Chemistry Angiotensin-(1-7): A Peptide Hormone with Anti-Cancer Activity
Current Medicinal Chemistry Rationale and Design of an Observational Study to Determine the Effects of Cholecalciferol on Hypertension, Proteinuria and Urinary MCP-1 in ADPKD
Current Hypertension Reviews Oxidative Stress Targeting Amyloid Beta Accumulation and Clearance in Alzheimer’s Disease: Insight into Pathological Mechanisms and Therapeutic Strategies
Current Psychopharmacology Marine Collagen as a Source of Bioactive Molecules: A Review
The Natural Products Journal